Full history for every metric is available with a Kvantra account
Ventyx Biosciences, Inc. (VTYX)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | $m | -148 | -117 | |||||
| Net profit | $m | -4 | -28 | -84 | -108 | -193 | -135 | -107 |
| EPS reported | $ | -1.97 | -1.50 | |||||
| Operating cashflow per share | $ | -1.91 | -0.54 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -1.91 | -0.55 | |||||
| Free cash flow | $m | -131 | -88 | |||||
| Net debt | $m | -217 | -193 | |||||
| Book value equity | $m | 254 | 191 | |||||
| Book value per share | $ | 3.71 | 2.68 | |||||
| Number of shares | m | 68.48 | 71.3 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 0.59 | 5.25 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -1.14 | -11.43 | |||||
| EV/EBITDA LTM | x | -1.00 | -7.69 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -90.10% | -4.99% | |||||
| FCF Yield | % | -87.43% | -8.75% | |||||
| Quality | ||||||||
| ROE | % | -53.19% | -24.86% | |||||
| ROIC | % | -56.05% | -26.92% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -12.15 | -8.77 | |||||
| Net Debt/EBITDA | x | 0.12 | 0.44 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -144.91% | -19.18% | |||||
| Net debt/Equity | x | -0.86 | -1.01 | |||||
| Gross debt/equity | x | 0.04 | 0.05 | |||||
Company overview
Ventyx Biosciences, Inc. is a biopharmaceutical company in the clinical development phase, specializing in the creation of small molecule therapeutics for inflammatory and autoimmune disorders. The company's primary investigational drug, VTX958, a tyrosine kinase type 2 (TYK2) inhibitor, is currently undergoing Phase I clinical trials. This compound aims to address a range of immune-mediated conditions, including psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. Among its pipeline assets is VTX002, an oral sphingosine 1 phosphate receptor 1 (S1P1) modulator, which has advanced to Phase II clinical studies for the treatment of ulcerative colitis. Additionally, VTX2735, a peripherally targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor, is in Phase I development, intended to combat systemic inflammatory diseases affecting cardiovascular, hepatic, renal, and rheumatologic systems. Furthermore, Ventyx is engaged in the development of CNS-penetrant NLRP3 inhibitors, with the objective of providing therapies for neurological ailments such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis. Founded in 2018, Ventyx Biosciences, Inc. is headquartered in Encinitas, California.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Ventyx Biosciences, Inc. (VTYX)
Ventyx Biosciences, Inc. is a biopharmaceutical company in the clinical development phase, specializing in the creation of small molecule therapeutics for inflammatory and autoimmune disorders. The company's primary investigational drug, VTX958, a tyrosine kinase type 2 (TYK2) inhibitor, is currently undergoing Phase I clinical trials. This compound aims to address a range of immune-mediated conditions, including psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. Among its pipeline assets is VTX002, an oral sphingosine 1 phosphate receptor 1 (S1P1) modulator, which has advanced to Phase II clinical studies for the treatment of ulcerative colitis. Additionally, VTX2735, a peripherally targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor, is in Phase I development, intended to combat systemic inflammatory diseases affecting cardiovascular, hepatic, renal, and rheumatologic systems. Furthermore, Ventyx is engaged in the development of CNS-penetrant NLRP3 inhibitors, with the objective of providing therapies for neurological ailments such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis. Founded in 2018, Ventyx Biosciences, Inc. is headquartered in Encinitas, California.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free